vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and Commercial Bancgroup, Inc. (CBK). Click either name above to swap in a different company.
ASCENTAGE PHARMA GROUP INTERNATIONAL is the larger business by last-quarter revenue ($32.6M vs $23.1M, roughly 1.4× Commercial Bancgroup, Inc.).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
AAPG vs CBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $23.1M |
| Net Profit | $11.4M | $9.5M |
| Gross Margin | 90.7% | — |
| Operating Margin | — | — |
| Net Margin | — | 41.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 9.7% |
| EPS (diluted) | — | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $23.1M | ||
| Q4 25 | — | $23.5M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | $32.6M | — |
| Q1 26 | — | $9.5M | ||
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | $11.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.8% | ||
| Q2 25 | — | — |
| Q1 26 | — | 41.3% | ||
| Q4 25 | — | 42.2% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | — | — |
| Q1 26 | — | $0.69 | ||
| Q4 25 | — | $0.72 | ||
| Q3 25 | — | $0.77 | ||
| Q2 25 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $118.2M |
| Stockholders' EquityBook value | — | — |
| Total Assets | — | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $154.8M | ||
| Q2 25 | — | — |
| Q1 26 | — | $118.2M | ||
| Q4 25 | — | $166.8M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $245.2M | ||
| Q2 25 | — | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
